Saccharomyces boulardii в терапии Helicobacter pylori-ассоциированных заболеваний

Дехнич Н.Н., Бобылев А.А. Saccharomyces boulardii в терапии Helicobacter pylori-ассоциированных заболеваний. Consilum Medicum. Гастроэнтерология. (Прил.). 2015; 1: 39–42.

________________________________________________

Dekhnich N.N., Bobylev A.А. Saccharomyces boulardii in treatment of Helicobacter pylori-associated diseases. Consilum Medicum. Gastroenterology. (Suppl.). 2015; 1: 39–42.

Читать PDF

Аннотация

Терапия Helicobacter pylori-ассоциированных заболеваний становится неудачной более чем в 20% случаев вследствие роста антибиотикорезистентности H. pylori к основным компонентам терапии и снижения приверженности пациента лечению. Подобная ситуация подталкивает к поиску новых альтернативных путей контроля над H. pylori-инфекцией. Применение Saccharomyces boulardii в составе препарата Энтерол как дополнительного компонента к стандартной тройной терапии увеличивает эффективность антихеликобактерного лечения и повышает переносимость терапии за счет уменьшения нежелательных лекарственных реакций.

Ключевые слова: Helicobacter pylori-ассоциированные заболевания, Helicobacter pylori, Saccharomyces boulardii, антихеликобактерная терапия.

________________________________________________

Treatment of Helicobacter pylori-associated disease is unsuccessful in more than 20% of the cases due to the growth of H. pylori antibiotic resistance to the major components of the therapy and the reduction of patient's treatment compliance. This situation makes researchers to search for new alternative ways of H. pylori infection control. The use of Saccharomyces boulardii as part of Enterol and as an additional component of the common triple therapy will increase the efficiency of anti-helicobacter therapy, and will improve the acceptability of therapy by reducing adverse drug reactions.

Key words: Helicobacter pylori-associated diseases, Helicobacter pylori, Saccharomyces boulardii, anti-helicobacter therapy.

Полный текст

Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Tong JL, Ran ZH, Shen J et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and side effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25: 155–68.
2. Guadalupe A et al. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014; 20 (6): 1450–69.
3. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии 2012; 1: 87–9. / Rekomendatsii Rossiyskoy gastroenterologicheskoy assotsiatsii po diagnostike i lecheniyu infektsii Helicobacter pylori u vzroslykh. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2012; 1: 87–9. [in Russian]
4. Cremonini F, Di Caro S, Covino M et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744–9.
5. Cindoruk M, Erkan G, Karakan T et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007; 12: 309–16.
6. Duman DG, Bor S, Ozütemiz O et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005; 17 (12): 1357–61.
7. Szajewska H еt al. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32 (9): 1069–79.
8. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr 2009; 168: 253–65.
9. Sakarya S, Gunay N. Saccharomyces boulardii expresses neuraminidase activity selective for a2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS 2014; 122 (10): 941–50.
10. Vandenbergh PA. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbiol Rev 1993; 12: 221–38.
11. Midolo PD, Lambert JR, Hull R et al. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol 1995; 79: 475–9.
12. Byrd JC, Yunker CK, Xu QS et al. Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterol 2000; 118: 1072–9.
13. Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2003; 17: 755–73.
14. Kelly SM, Pitcher MC, Farmery SM, Gibson GR. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom. Gastroenterology 1994; 107 (6): 1671–4.
15. Falsafi T, Valizadeh N, Najafi M et al. Culture of Helicobacter pylori from stool samples in children. Can J Microbiol 2007; 53 (3): 411–6.
16. Topping DI, Clifton PM. Short-Chain Fatty Acids and Human Colonic Function: Roles of Resistant Starch and Nonstarch Polysaccharides. Physiological Reviews 2001; 81 (3): 1031–64.

________________________________________________

1. Tong JL, Ran ZH, Shen J et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and side effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25: 155–68.
2. Guadalupe A et al. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol 2014; 20 (6): 1450–69.
3. Rekomendatsii Rossiyskoy gastroenterologicheskoy assotsiatsii po diagnostike i lecheniyu infektsii Helicobacter pylori u vzroslykh. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2012; 1: 87–9. [in Russian]
4. Cremonini F, Di Caro S, Covino M et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002; 97: 2744–9.
5. Cindoruk M, Erkan G, Karakan T et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 2007; 12: 309–16.
6. Duman DG, Bor S, Ozütemiz O et al. Efficacy and safety of Saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2005; 17 (12): 1357–61.
7. Szajewska H еt al. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010; 32 (9): 1069–79.
8. Vandenplas Y, Brunser O, Szajewska H. Saccharomyces boulardii in childhood. Eur J Pediatr 2009; 168: 253–65.
9. Sakarya S, Gunay N. Saccharomyces boulardii expresses neuraminidase activity selective for a2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS 2014; 122 (10): 941–50.
10. Vandenbergh PA. Lactic acid bacteria, their metabolic products and interference with microbial growth. FEMS Microbiol Rev 1993; 12: 221–38.
11. Midolo PD, Lambert JR, Hull R et al. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol 1995; 79: 475–9.
12. Byrd JC, Yunker CK, Xu QS et al. Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterol 2000; 118: 1072–9.
13. Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2003; 17: 755–73.
14. Kelly SM, Pitcher MC, Farmery SM, Gibson GR. Isolation of Helicobacter pylori from feces of patients with dyspepsia in the United Kingdom. Gastroenterology 1994; 107 (6): 1671–4.
15. Falsafi T, Valizadeh N, Najafi M et al. Culture of Helicobacter pylori from stool samples in children. Can J Microbiol 2007; 53 (3): 411–6.
16. Topping DI, Clifton PM. Short-Chain Fatty Acids and Human Colonic Function: Roles of Resistant Starch and Nonstarch Polysaccharides. Physiological Reviews 2001; 81 (3): 1031–64.

Авторы

Н.Н.Дехнич*, А.А.Бобылев

ГБОУ ВПО Смоленский государственный медицинский университет Минздрава России. 214019, Россия, Смоленск, ул. Крупской, д. 28
*n.dekhnich@mail.ru

________________________________________________

N.N.Dekhnich*, A.А.Bobylev

The Smolensk State Medical University of the Ministry of Health of the Russian Federation. 214019, Russian Federation, Smolensk, ul. Krupskoi, d. 28
*n.dekhnich@mail.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.